Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumor growth inhibition modeling to support the starting dose for dacomitinib.

CPT: pharmacometrics & systems pharmacology - 1 Sept 2022

Fostvedt Luke K, Nickens Dana J, Tan Weiwei, Parivar Kourosh

Abstract excerpt

Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor for first-line treatment of patients with metastatic non-small cell lung cancer and EGFR-activating mutations. A high rate of dose reductions in the pivotal trial led to an observed inverse exposure-response (ER) relationship with the primary end points. Three ER models were developed to determine if the starting dose from the pivotal...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Quinazolinones

Source

Open in PubMed Open full text

Identifiers

PMID: 35818811
DOI: 10.1002/psp4.12841
PMCID: PMC9893889

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumor growth inhibition modeling to support the starting dose for dacomitinib.PMID 35818811Read ↗

Effects of Dose Modifications on the Safety and Efficacy of Dacomitinib for EGFR Mutation-Positive Non-Small-Cell Lung CancerSemantic proximity Read ↗

Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042).Semantic proximity Read ↗

Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer.Semantic proximity Read ↗

Phase I/II Study of Erlotinib to Determine the Optimal Dose in Patients With Non-Small Cell Lung Cancer Harboring Only EGFR Mutations.Semantic proximity Read ↗

Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.Semantic proximity Read ↗

Should the choice of BOIN design parameter<i>p.tox</i>only depend on the target DLT rate?Semantic proximity Read ↗

Exposure-response analyses of BRAF- and MEK-inhibitors dabrafenib plus trametinib in melanoma patients.Semantic proximity Read ↗

Costing ‘the’ MTDSemantic proximity Read ↗

Should the Choice of BOIN Design Parameter <em>p.tox</em> only Depend on the Target DLT Rate?Semantic proximity Read ↗

Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors.Semantic proximity Read ↗

Disparities in dosing, drug reduction, and drug discontinuation among US FDA approved tyrosine kinase inhibitorsSemantic proximity Read ↗

Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.